Wedbush analyst Robert Driscoll raised the firm’s price target on Tyra Biosciences (TYRA) to $37 from $30 and keeps an Outperform rating on the shares. The firm also added the name to the Wedbush Best Ideas List ahead of a busy 2026, with data from two ongoing Phase 2 studies in intermediate-grade non-muscle invasive bladder cancer and in achondroplasia.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA: